Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

First patient dosed in phase I study of NBTXR-3 in pancreatic cancer

Oct. 14, 2020

Shanghai Ringene Biopharma synthesizes new BRD and/or c-Myc inhibitors

Oct. 14, 2020

Sumitomo Dainippon Pharma Oncology presents new PKM2 activators

Oct. 14, 2020

Additional interim data presented for WP-1066 in adult glioblastoma

Oct. 14, 2020

Interim data from FIDES-02 study of derazantinib in advanced urothelial cancer

Oct. 14, 2020

Kinnate Biopharma discovers c-RAF inhibitors

Oct. 14, 2020

Amgen studies AMG-256 for advanced solid tumors in phase I trial

Oct. 14, 2020

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical present new ERK inhibitors

Oct. 13, 2020

New HDAC6 inhibitors discovered at 2681603 Ontario

Oct. 13, 2020

Janssen Pharmaceutica discloses new MAP4K1 inhibitors

Oct. 13, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...